keyword
MENU ▼
Read by QxMD icon Read
search

antipsychotic switching

keyword
https://www.readbyqxmd.com/read/27875914/second-generation-antipsychotics-in-real-life-paediatric-patients-adverse-drug-reactions-and-clinical-outcomes-of-drug-switch
#1
Concetta Rafaniello, Marco Pozzi, Simone Pisano, Carmen Ferrajolo, Silvana Bertella, Liberata Sportiello, Carla Carnovale, Maria Giuseppa Sullo, Dario Cattaneo, Marta Gentili, Renata Rizzo, Antonio Pascotto, Elisa Mani, Laura Villa, Maria Pia Riccio, Serena Sperandeo, Renato Bernardini, Carmela Bravaccio, Emilio Clementi, Massimo Molteni, Francesco Rossi, Sonia Radice, Annalisa Capuano
OBJECTIVE: Gap in knowledge on benefit/risk ratio of second generation antipsychotics (SGA) in the paediatric population represents a challenge for the scientific community. This study aims to analyse all suspected adverse drug reactions (ADRs) to SGA observed during the study period; compare the safety profiles of risperidone and aripiprazole; evaluate the effect of switching from risperidone to aripiprazole or to a first generation antipsychotic (FGA). METHODS: Prospective analysis of spontaneously reported ADRs concerning 184 paediatric outpatients between 2012 and 2014...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27855483/prediction-of-relapse-after-discontinuation-of-antipsychotic-treatment-in-alzheimer-s-disease-the-role-of-hallucinations
#2
Anjali N Patel, Seonjoo Lee, Howard F Andrews, Gregory H Pelton, Susan K Schultz, David L Sultzer, Jacobo Mintzer, Danilo de la Pena, Sanjay Gupta, Sylvia Colon, Corbett Schimming, Bruce Levin, D P Devanand
OBJECTIVE: In Alzheimer's disease, antipsychotic medications are often used for a period, with relief of symptoms, and then discontinued, after which relapse may occur. The authors sought to determine which neuropsychiatric symptoms predict relapse. METHOD: In the Antipsychotic Discontinuation in Alzheimer's Disease trial, 180 patients with Alzheimer's disease and symptoms of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who responded (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo for 16 weeks, or to receive placebo for 32 weeks...
November 18, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/27848269/evidence-based-pharmacotherapy-of-treatment-resistant-unipolar-depression
#3
Markus Dold, Siegfried Kasper
Treatment resistance to the antidepressive pharmacotherapy represents one of the most important clinical challenges in the pharmacological management of unipolar depression. In this review, we aimed to summarise the evidence for various pharmacological treatment options in therapy-resistant unipolar depression derived from clinical trials, systematic reviews, meta-analyses and treatment guidelines. The first measure in case of insufficient response to the initial antidepressant monotherapy contains the debarment of 'pseudo-resistance', potentially caused by inadequate dose and treatment duration of the antidepressant, insufficient plasma levels, non-compliance of the patient regarding medication intake or relevant psychiatric and/or somatic comorbidities...
November 16, 2016: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/27828697/aripiprazole-induced-hyperlipidemia-an-update
#4
Caroline Tarraf, Wadih J Naja
OBJECTIVE: To review the literature on the metabolic side effects of aripiprazole. Three cases of aripiprazole-induced hypertriglyceridemia are also presented. DATA SOURCES: A search was conducted of English-language articles and abstracts (meta-analyses, randomized controlled trials, clinical trials, naturalistic open-label trials, reviews, and case reports) published up to August 31, 2014, in electronic databases (PubMed, MEDLINE). STUDY SELECTION: Free-text and MeSH search keywords included aripiprazole, cholesterol, triglyceride, lipid profile, hyperlipidemia, and hypercholesterolemia and their differing terminations and combinations...
August 25, 2016: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/27815602/switching-from-oral-atypical-antipsychotic-monotherapy-to-paliperidone-palmitate-once-monthly-in-non-acute-patients-with-schizophrenia-a-prospective-open-label-interventional-study
#5
Andreas Schreiner, Asaf Caspi, Paul Bergmans, Pierre Cherubin, Sofia Keim, Elsa Lara, Irina Pinchuk, Daniel Schuepbach, Sajid Suleman, Ludger Hargarter
RATIONALE: Long-acting injectable antipsychotic therapies may offer benefits over oral antipsychotics in patients with schizophrenia. OBJECTIVE: This study aimed to explore the safety, tolerability, and treatment response of paliperidone palmitate once-monthly in non-acute but symptomatic adult patients switched from previously unsuccessful monotherapy with frequently used oral atypical antipsychotics. METHODS: This was a post hoc analysis of a prospective, interventional, single-arm, international, multicenter, open-label, 6-month study...
November 5, 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27800283/prolactin-levels-after-switching-to-paliperidone-palmitate-in-patients-with-schizophrenia
#6
Masaru Nakamura, Takahiko Nagamine, Goro Sato, Kazue Besho
Objective: The aim of this study was to investigate the tolerability and efficacy of paliperidone palmitate and its effect on the levels of prolactin in patients with schizophrenia. Method: A prospective study was carried out in 22 Japanese middle-aged patients with schizophrenia who were switched from paliperidone-extended release or risperidone long-acting injectable to paliperidone palmitate for a minimum of 12 months. Psychotic symptoms using the 18-item Brief Psychiatric Rating Scale, extrapyramidal symptoms using 9-item Drug-induced Extrapyramidal Symptoms Scale, and plasma prolactin levels using fasting blood samples were assessed at Baseline, and one, three, six, and 12 months...
May 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27799749/physician-and-patient-benefit-risk-preferences-from-two-randomized-long-acting-injectable-antipsychotic-trials
#7
Eva G Katz, Brett Hauber, Srihari Gopal, Angie Fairchild, Amy Pugh, Rachel B Weinstein, Bennett S Levitan
PURPOSE: To quantify clinical trial participants' and investigators' judgments with respect to the relative importance of efficacy and safety attributes of antipsychotic treatments for schizophrenia, and to assess the impact of formulation and adherence. METHODS: Discrete-choice experiment surveys were completed by patients with schizophrenia and physician investigators participating in two phase-3 clinical trials of paliperidone palmitate 3-month long-acting injectable (LAI) antipsychotic...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27776390/amisulpride-switching-in-schizophrenic-patients-who-showed-suboptimal-effect-and-or-tolerability-to-current-antipsychotics-in-a-naturalistic-setting-an-explorative-study
#8
Yongmin Kim, Sheng-Min Wang, Kyung-Phil Kwak, Ho-Kyoung Yoon, Chi-Un Pae, Jung-Jin Kim, Won-Myong Bahk
Objective: Despite numerous atypical antipsychotics (AAP) available, many patients with schizophrenia still experience lack of efficacy and persistent side-effects. Switching from one AAP to another with a different side-effect profile has become a common clinical strategy. We aimed to investigate effect of switching to amisulpride in patients who showed suboptimal effect and /or tolerability to current antipsychotics treatment. Methods: This was a 6-week, prospective, multicenter, open-label, flexible-dose study in patients with schizophrenia...
November 30, 2016: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27738379/effects-of-discontinuation-of-paliperidone-long-acting-injectable-after-switching-from-risperidone-long-acting-injectable-switching
#9
Takafumi Watanabe, Atsurou Yamada
BACKGROUND: Risperidone long-acting injection (RLAI) is increasingly being switched to paliperidone palmitate (PP) because of several benefits. However, this switching is not always successful. METHODS: We examined patient profiles following discontinuation of PP after switching from RLAI. We collected the electronic records of 24 patients with schizophrenia who had switched from RLAI to PP treatment at our hospital between November 2013 and March 2014. Twelve patients continued PP injection for over 1 year (PP-continuers), the other 12 patients discontinued within 1 year (PP-discontinuers), and both groups were followed up until December 31, 2014...
August 15, 2016: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/27659709/palmitoylation-of-the-carboxyl-terminal-tail-of-dopamine-d4-receptor-is-required-for-surface-expression-endocytosis-and-signaling
#10
Xiaowei Zhang, Kyeong-Man Kim
The amino acid sequences and signaling pathways of D2-like dopamine receptors (D2R, D3R, and D4R) are highly conserved. D4R has been suggested to be associated with novelty seeking, and binds with high affinity to an atypical antipsychotic drug with fewer motor function-related side effects than typical neuroleptics. A study comparing D2R and D3R reported that palmitoylation is important for the proper functioning of D3R. Although D4R is a member of the D2-like receptor family, its palmitoylation status and the functional significance of any such posttranslational modification are unknown...
October 14, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27658832/treatment-patterns-of-schizophrenia-based-on-the-data-from-seven-central-and-eastern-european-countries
#11
Monika Szkultecka-Dębek, Katarzyna Miernik, Jarosław Stelmachowski, Miro Jakovljević, Vlado Jukić, Kaire Aadamsoo, Sven Janno, István Bitter, Judit Tolna, Marek Jarema, Slobodan Jankovic, Jan Pecenak, Livia Vavrusova, Rok Tavčar, Jacek Walczak, Darren Talbot, Joanna Augustyńska
OBJECTIVE: The aim is to analyze how schizophrenia is pharmacologically treated in seven CEE countries: Croatia, Estonia, Hungary, Poland, Serbia, Slovakia and Slovenia. METHODS: Psychiatrists from selected centers in each of participating countries were asked to complete a pre-defined questionnaire on their current clinical practice. Information on protocols and resource utilization in schizophrenia treatment was included and derived from randomly selected patient medical records...
September 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/27627971/marked-improvement-of-meige-syndrome-in-a-japanese-male-patient-with-schizophrenia-after-switching-from-risperidone-to-paliperidone-a-case-report
#12
Reiji Yoshimura, Hikaru Hori, Asuka Katsuki, Kiyokazu Atake
Meige syndrome is a relatively rare type of oral facial dystonia. The dominant symptoms involve involuntary eye blinking and chin thrusting. Some patients may experience excessive tongue protrusion, squinting, muddled speech, or uncontrollable contraction of the platysma muscle. A 44-year-old Japanese male was suffering from schizophrenia. The initial presentation of his psychosis consisted of auditory hallucinations, delusions of persecution, psychomotor excitement, loosening association, and restlessness...
September 2016: Journal of UOEH
https://www.readbyqxmd.com/read/27580887/-antipsychotic-induced-tardive-syndromes
#13
W Wolfgang Fleischhacker, Alex Hofer, Christian Jagsch, Walter Pirker, Georg Psota, Hans Rittmannsberger, Klaus Seppi
Tardive dyskinesia (TD) remains a relevant clinical problem despite the increasing use of new-generation antipsychotics. Antipsychotic-induced tardive syndromes are difficult to treat and have a low tendency of remission. Therefore, prophylaxis is of utmost importance, with the responsible use of antipsychotics as a prime desideratum. With respect to managing tardive dyskinesia, discontinuing the antipsychotic, if possible, albeit not backed up by unequivocal evidence, is still the main recommendation. If this is not possible, the switch to an antipsychotic with a lower TD risk is the next-preferred option...
September 2016: Neuropsychiatrie: Klinik, Diagnostik, Therapie und Rehabilitation
https://www.readbyqxmd.com/read/27574460/use-of-combinatorial-pharmacogenomic-testing-in-two-cases-from-community-psychiatry
#14
Eve S Fields, Raymond A Lorenz, Joel G Winner
This report describes two cases in which pharmacogenomic testing was utilized to guide medication selection for difficult to treat patients. The first patient is a 29-year old male with bipolar disorder who had severe akathisia due to his long acting injectable antipsychotic. The second patient is a 59-year old female with major depressive disorder who was not responding to her medication. In both cases, a proprietary combinatorial pharmacogenomic test was used to inform medication changes and improve patient outcomes...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27531181/effects-of-aripiprazole-once-monthly-on-symptoms-of-schizophrenia-in-patients-switched-from-oral-antipsychotics
#15
Timothy Peters-Strickland, Cathy Zhao, Pamela P Perry, Anna Eramo, Phyllis M Salzman, Robert D McQuade, Brian R Johnson, Raymond Sanchez
OBJECTIVE: To assess the effects of aripiprazole once-monthly 400 mg (AOM 400) on clinical symptoms and global improvement in schizophrenia after switching from an oral antipsychotic. METHODS: In a multicenter, open-label, mirror-image, naturalistic study in patients with schizophrenia (>1 year, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision [DSM-IV-TR] criteria), changes in efficacy measures were assessed during prospective treatment (6 months) with AOM 400 after switching from standard-of-care oral antipsychotics...
August 17, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27516021/clinical-and-biological-outcomes-of-prolonged-treatment-with-haloperidol-in-schizophrenia
#16
Mihai Mutică, Ileana Marinescu, Felicia Militaru, Mihail Cristian Pîrlog, Ion Udriştoiu
Paranoid schizophrenia with long-term course is a challenge for the clinical and therapeutic research, particularly because chronic course is difficult to identify due to the high rate of mortality in this category of patients. The therapeutic stability on an antipsychotic molecule (haloperidol) is indeed an exception, since the current trend in the case of unfavorable course is based on therapeutic versatility and polypharmacy. Haloperidol is the first-generation antipsychotic that is referred in the therapeutic guidelines as the "golden standard" regarding its efficacy on positive symptoms...
2016: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/27514298/sexual-dysfunction-due-to-psychotropic-medications
#17
REVIEW
Anita H Clayton, Andrew R Alkis, Nishant B Parikh, Jennifer G Votta
Sexual functioning is important to assess in patients with psychiatric illness as both the condition and associated treatment may contribute to sexual dysfunction (SD). Antidepressant medications, mood stabilizers, antipsychotics, and antianxiety agents may be associated with SD related to drug mechanism of action. Sexual adverse effects may be related to genetic risk factors, impact on neurotransmitters and hormones, and psychological elements. Effective strategies to manage medication-induced sexual dysfunction are initial choice of a drug unlikely to cause SD, switching to a different medication, and adding an antidote to reverse SD...
September 2016: Psychiatric Clinics of North America
https://www.readbyqxmd.com/read/27487259/effects-of-switching-to-aripiprazole-from-current-atypical-antipsychotics-on-subsyndromal-symptoms-and-tolerability-in-patients-with-bipolar-disorder
#18
Young Sup Woo, Won-Myong Bahk, Young-Min Park, Sangkeun Chung, Bo-Hyun Yoon, Seunghee Won, Jeong Goo Lee, Hwang-Bin Lee, Won Kim, Jong-Hyun Jeong, Kwanghun Lee, Moon-Doo Kim
We evaluated the effectiveness of aripiprazole among bipolar patients who had switched to this medication as a result of difficulty maintaining on their prestudy atypical antipsychotics (AAPs) because of subsyndromal mood symptoms or intolerance. This study included 77 bipolar patients who were in syndromal remission with an AAP as monotherapy or with an AAP combined with a mood stabilizer(s) who needed to switch from their present AAP because of subsyndromal symptoms or intolerance. At 24 weeks after switching to aripiprazole, the remission rates on the Montgomery-Åsberg Depression Rating Scale (MADRS) and on both the MADRS and the Young Mania Rating Scale were increased significantly in the full sample and in the inefficacy subgroup...
September 2016: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27442981/lai-versus-oral-a-case-control-study-on-subjective-experience-of-antipsychotic-maintenance-treatment
#19
F Pietrini, M Spadafora, L Tatini, G A Talamba, C Andrisano, G Boncompagni, M Manetti, V Ricca, A Ballerini
BACKGROUND: To present real-world evidence on the differences between long-acting injectable (LAI) and oral antipsychotic maintenance treatment (AMT) in terms of subjective well-being, attitudes towards drug and quality of life in a sample of remitted schizophrenic subjects. METHODS: Twenty outpatients with remitted schizophrenia treated with either olanzapine or paliperidone and switching from the oral to the LAI formulation of their maintenance treatment were recruited before the switch (LAI-AMT group)...
September 2016: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/27438182/comparing-the-effectiveness-and-safety-of-the-addition-of-and-switching-to-aripiprazole-for-resolving-antipsychotic-induced-hyperprolactinemia-a-multicenter-open-label-prospective-study
#20
Hui Woo Yoon, Jung Suk Lee, Sang Jin Park, Seon-Koo Lee, Won-Jung Choi, Tae Yong Kim, Chang Hyung Hong, Jeong-Ho Seok, Il-Ho Park, Sang Joon Son, Daeyoung Roh, Bo-Ra Kim, Byung Ook Lee
OBJECTIVES: Hyperprolactinemia is an important but often overlooked adverse effect of antipsychotics. Several studies have shown that switching to or adding aripiprazole normalizes antipsychotic-induced hyperprolactinemia. However, no study has directly compared the effectiveness and safety of the 2 strategies. METHODS: A total of 52 patients with antipsychotic-induced hyperprolactinemia were recruited. Aripiprazole was administered to patients with mild hyperprolactinemia (serum prolactin level < 50 ng/mL)...
July 19, 2016: Clinical Neuropharmacology
keyword
keyword
88298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"